Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366308> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4313366308 endingPage "136.21" @default.
- W4313366308 startingPage "136.21" @default.
- W4313366308 abstract "Abstract The classical approach to vaccine development establishes an effective, lasting memory response by challenging an organism with an antigen/adjuvant combination to prime the immune system against the antigen challenge. However, with respect to cancer vaccine development, this approach has often failed to elicit positive outcomes. This is, in part, due to the ability of tumor cells to downregulate specific antigens and forego immune surveillance. The objective of this study is to develop a treatment strategy that induces expression of cancer testis antigens (CTAs) on tumor cells while eliciting a strong and lasting immune response against these CTAs. CTAs are derived from proteins only expressed in immune-privileged sites under normal conditions, but de novo expression can be induced following treatment with a DNA methyltransferase inhibitor, such as guadecitabine (GUA). Previous publications have shown that intratumoral injections of a TLR9 agonist, CpG, results in an immune response against antigens expressed within the treated tumor. Our experiments have shown that 4T1 cells, a mouse mammary carcinoma, treated in vitro with GUA resulted in increased expression of CTAs as measured by flow cytometry. In addition, BALB/c mice challenged with 4T1 cells then treated with GUA + CpG resulted in depletion of myeloid derived suppressor cells and significantly reduced tumor burden. Tumor-bearing mice that received GUA treatment followed by adoptive T-cell therapy (ATC) also had significantly smaller tumors compared to the ATC only group. These findings warrant further investigation into whether treatment with GUA prior to treatment with CpG results in a lasting memory response against CTAs." @default.
- W4313366308 created "2023-01-06" @default.
- W4313366308 creator A5003429713 @default.
- W4313366308 creator A5068767093 @default.
- W4313366308 date "2019-05-01" @default.
- W4313366308 modified "2023-09-26" @default.
- W4313366308 title "Guadecitabine, in combination with a TLR9 agonist, promotes anti-cancer immunity in BALB/c mice bearing 4T1 mouse mammary carcinoma" @default.
- W4313366308 doi "https://doi.org/10.4049/jimmunol.202.supp.136.21" @default.
- W4313366308 hasPublicationYear "2019" @default.
- W4313366308 type Work @default.
- W4313366308 citedByCount "0" @default.
- W4313366308 crossrefType "journal-article" @default.
- W4313366308 hasAuthorship W4313366308A5003429713 @default.
- W4313366308 hasAuthorship W4313366308A5068767093 @default.
- W4313366308 hasConcept C104317684 @default.
- W4313366308 hasConcept C121608353 @default.
- W4313366308 hasConcept C147483822 @default.
- W4313366308 hasConcept C150194340 @default.
- W4313366308 hasConcept C190727270 @default.
- W4313366308 hasConcept C203014093 @default.
- W4313366308 hasConcept C22801619 @default.
- W4313366308 hasConcept C2776090121 @default.
- W4313366308 hasConcept C2776662205 @default.
- W4313366308 hasConcept C2777701055 @default.
- W4313366308 hasConcept C2777863537 @default.
- W4313366308 hasConcept C2779138994 @default.
- W4313366308 hasConcept C502942594 @default.
- W4313366308 hasConcept C54355233 @default.
- W4313366308 hasConcept C55493867 @default.
- W4313366308 hasConcept C86803240 @default.
- W4313366308 hasConcept C8891405 @default.
- W4313366308 hasConcept C90375314 @default.
- W4313366308 hasConceptScore W4313366308C104317684 @default.
- W4313366308 hasConceptScore W4313366308C121608353 @default.
- W4313366308 hasConceptScore W4313366308C147483822 @default.
- W4313366308 hasConceptScore W4313366308C150194340 @default.
- W4313366308 hasConceptScore W4313366308C190727270 @default.
- W4313366308 hasConceptScore W4313366308C203014093 @default.
- W4313366308 hasConceptScore W4313366308C22801619 @default.
- W4313366308 hasConceptScore W4313366308C2776090121 @default.
- W4313366308 hasConceptScore W4313366308C2776662205 @default.
- W4313366308 hasConceptScore W4313366308C2777701055 @default.
- W4313366308 hasConceptScore W4313366308C2777863537 @default.
- W4313366308 hasConceptScore W4313366308C2779138994 @default.
- W4313366308 hasConceptScore W4313366308C502942594 @default.
- W4313366308 hasConceptScore W4313366308C54355233 @default.
- W4313366308 hasConceptScore W4313366308C55493867 @default.
- W4313366308 hasConceptScore W4313366308C86803240 @default.
- W4313366308 hasConceptScore W4313366308C8891405 @default.
- W4313366308 hasConceptScore W4313366308C90375314 @default.
- W4313366308 hasIssue "1_Supplement" @default.
- W4313366308 hasLocation W43133663081 @default.
- W4313366308 hasOpenAccess W4313366308 @default.
- W4313366308 hasPrimaryLocation W43133663081 @default.
- W4313366308 hasRelatedWork W1975011225 @default.
- W4313366308 hasRelatedWork W1990565656 @default.
- W4313366308 hasRelatedWork W1995781391 @default.
- W4313366308 hasRelatedWork W2032597637 @default.
- W4313366308 hasRelatedWork W2160959672 @default.
- W4313366308 hasRelatedWork W2275222446 @default.
- W4313366308 hasRelatedWork W2415009972 @default.
- W4313366308 hasRelatedWork W2418534979 @default.
- W4313366308 hasRelatedWork W3042789857 @default.
- W4313366308 hasRelatedWork W4313366308 @default.
- W4313366308 hasVolume "202" @default.
- W4313366308 isParatext "false" @default.
- W4313366308 isRetracted "false" @default.
- W4313366308 workType "article" @default.